Key Takeaways
- U.S. Sen. Dave McCormick toured Penn’s AIRFoundry to see how AI, robotics, and automation are shortening biomedical discovery timelines from years to weeks.
- Researchers say AI can cut the typical 10‑year, hundreds‑of‑millions‑to‑billions‑of‑dollars drug‑search process down to roughly six months.
- The lab has spun‑off startups such as InfiniFluidics, which uses AI‑driven robotics to accelerate RNA‑based drug production.
- Penn’s new undergraduate AI degree—the first among Ivy League schools—has already graduated its first cohort and is projected to grow to 250 students next year.
- Program leaders emphasize that AI’s value lies not only in advancing the technology itself but in its cross‑disciplinary impact on health, robotics, agriculture, and other sectors.
Visit Highlights AI’s Role in Biomedical Research
On Friday, May 15, 2026, U.S. Senator Dave McCormick, R‑Pa., visited the AIRFoundry laboratory located at One uCity Square near the University of Pennsylvania campus. The senator toured the AI‑driven research hub, which is funded by the National Science Foundation and integrates artificial intelligence, robotics, and automation to accelerate the development of RNA‑based medicines, drug‑delivery systems, and broader biotechnologies. During the tour, McCormick remarked, “Every time I come here for a visit, I leave just inspired by all the wonderful, incredible discoveries and progress,” underscoring his optimism about the lab’s potential to transform therapeutic innovation.
AIRFoundry’s AI‑Powered Infrastructure
AIRFoundry operates as an incubator where computer scientists, bioengineers, and molecular biologists collaborate on projects that leverage machine learning models to parse massive datasets, predict promising drug formulations, and automate repetitive laboratory tasks. By embedding AI into the experimental workflow, the lab aims to replace traditional trial‑and‑error approaches with data‑guided design cycles that can rapidly iterate through thousands of virtual candidates before any wet‑lab work begins. This integration of robotics allows for high‑throughput synthesis and testing, further reducing manual labor and human error.
From Years to Weeks: Accelerating Drug Development
Researchers at AIRFoundry emphasized that the adoption of AI has compressed what used to take years into a matter of weeks. Jake Gardner, an assistant professor of computer science who works at the lab, explained this shift to Senator McCormick: “Years of work become weeks of work, and that’s sort of the compression that you see when you use AI to do these things.” The statement captures the core promise of AI‑augmented research: the ability to sift through chemical space, predict efficacy, and optimize delivery mechanisms at a speed unattainable by conventional methods.
Cost and Timeline Reductions in the Drug Pipeline
Andrew Hanna, a bioengineering doctoral student at AIRFoundry, elaborated on the economic implications of this acceleration. He noted that pharmaceutical companies typically spend a decade and “hundreds of millions to billions of dollars just looking for a potential candidate that they’ll then take through the clinical pipeline.” Hanna added, “The goal is to turn that from like a 10‑year process to like a six‑month process.” Such a reduction would not only lower R&D expenditures but also expedite patient access to life‑saving therapies, particularly for rare diseases where market incentives are limited.
Commercialization Spotlight: InfiniFluidics
The visit also highlighted the entrepreneurial spirit emanating from Penn’s research ecosystem. Several researchers described how university labs have spawned startup companies aiming to translate AI innovations into marketable products. One notable example is InfiniFluidics, co‑founded by Daeyeon Lee, a professor of chemical and biomolecular engineering. Lee described the company’s prototype system, which “uses robotics and AI‑processing to speed up the creation of RNA‑based drug treatments.” He envisioned the technology being adopted by hospitals, research labs, and pharmaceutical firms seeking faster, more reliable production pipelines.
Interdisciplinary Collaboration at InfiniFluidics
Daeyeon Lee further emphasized the collaborative nature of the project, stating, “This is a unique project even for Penn, which is known for interdisciplinarity. We have computer scientists that are building AI platforms so that we can design experiments for people, but then we have people working in molecular biology. We have people like me or engineers that come together to build these facilities and help researchers.” This quote illustrates how the convergence of AI expertise, biological knowledge, and engineering prowess is essential for creating tools that are both technically robust and biologically relevant.
Penn’s Undergraduate AI Program Grows
Beyond the lab’s immediate research, Penn is cultivating the next generation of AI talent through its newly launched undergraduate degree in artificial intelligence—the first such program offered by an Ivy League institution. The inaugural cohort of six students graduated this weekend, having completed a curriculum that includes foundational AI courses as well as specialized tracks such as “AI for health” and “AI for robotics.” George Pappas, director of Penn’s AI program, shared his outlook with Senator McCormick: “It’s not just advancing AI, but how to impact other disciplines and other sectors of the economy through AI.” He added that the program anticipates enrollment to expand to roughly 250 students within the next year.
Broader Implications for Health and Beyond
Senator McCormick’s tour underscored a vision in which AI serves as a catalyst not only for faster drug discovery but also for cross‑sector innovation. By shortening development cycles, cutting costs, and fostering startup formation, AI‑driven platforms like those at AIRFoundry could reshape how therapies are conceived, tested, and delivered. Moreover, the skills being cultivated in Penn’s undergraduate AI program promise to feed a workforce capable of applying these technologies to agriculture, veterinary science, environmental monitoring, and other fields that stand to benefit from rapid, data‑driven innovation. As the senator departed, he left with a renewed sense of optimism that continued investment in AI research will yield tangible improvements in public health and economic competitiveness.